The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy

Title:The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy

Volume: 24 Issue: 39

Author(s): Seyed A. Javadinia, Soodabeh Shahidsales, Azar Fanipakdel, Asma Mostafapour, Mona Joudi-Mashhad, Gordon A. Ferns and Amir Avan*

Affiliation:

• Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran

Keywords: PI3K/AKT/mTOR pathway, microRNAs, esophageal cancer, rapamycin, translation, transcription.

Abstract: The Phosphatidylinositol 3-kinase/AKT/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) pathway has a critical regulatory role in cell biology including translation, transcription, and autophagy. Dysregulation of this pathway is involved in the pathogenesis, development, and prognosis of esophageal cancer that has been assessed in the recent years and its potential as a target in therapy. This report summarizes the current knowledge about PI3K/AKT/mTOR pathway and its cross-talk with a focus on the value of targeting this pathway as a potential therapeutic target in the treatment of esophageal cancer.

Cite this article as:

Javadinia A. Seyed, Shahidsales Soodabeh , Fanipakdel Azar , Mostafapour Asma , Joudi-Mashhad Mona , Ferns A. Gordon and Avan Amir *, The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190110143258